Bioanalysis
A Snapshot of the Webinar “Development of a Cell-Based Assay”
Cell-based assays are usually used to represent the mechanism of action (MoA) of the administered drug. Throughout various stages of drug development, they may be used for different purposes. These include detecting the presence of neutralizing antibodies (NAbs) and evaluating a drug’s potency. In Altasciences’ webinar, “Development of a Cell-Based Assay,” Dr.
Development of a Surrogate Cerebrospinal Fluid Matrix for Quantitative Analysis of Antisense Oligonucleotides by Hybridization LC-MS/MS
A Novel Method for Performing Linearity Assessments in Whole Blood Prepared Using a Lyse/No Wash Procedure
ISSUE NO. 27 — The Complexities of Early-Phase Ophthalmic Drug Development
Ophthalmic medications have a particular set of challenges that can impact their speedy and successful path to market. From prototype formulation through preclinical testing, early-phase clinical and manufacturing and development, ophthalmic drug development presents with specific and unique complexities. It is best to entrust drug development to a partner with regulatory knowledge, technical expertise, and a thorough understanding of the market in this growing therapeutic area. From current reality to future trends, being at the forefront of ophthalmic drug development delivers tangible benefits to sponsors.
In Issue 27 of The Altascientist, we dive into all areas of ophthalmic drug development, including:
- Prototype development, formulation, and manufacturing
- Preparing for first-in-human studies
- Species and strain selection parameters
- Routes of administration
- Specialized ocular assessments and equipment
- bioanalysis
- Phase I clinical research
- Phase II to commercialization
Three case studies are also included!
Five Lesser-Known Uses for PCR
PCR testing has been in the spotlight as the most reliable way of screening for COVID-19 in patients since the beginning of the pandemic. But what is PCR? And what are its other uses?
Key Biomarkers of Immunomodulation: Complement Factors and Cytokines
Quantitation of the COVID-19 Neutralizing Antibody Bamlanivimab* Using Mitra® Microsampling and Mass Spectrometry
Comparing Cytokine Data to In-Life Parameters on Nonhuman Primates in Nonclinical Toxicology Studies
Parallelism Challenges When Using Commercial Kits for Biomarker Quantitation
One Integrated Solution for Meeting Your Preclinical to Clinical Drug Development Needs